[go: up one dir, main page]

SI2861229T1 - Farmacevtski sestavek, ki vsebuje nikotinsko kislino in/ali nikotinamid in/ali triptofan, za pozitivno vplivanje na črevesno mikrobioto - Google Patents

Farmacevtski sestavek, ki vsebuje nikotinsko kislino in/ali nikotinamid in/ali triptofan, za pozitivno vplivanje na črevesno mikrobioto

Info

Publication number
SI2861229T1
SI2861229T1 SI201331842T SI201331842T SI2861229T1 SI 2861229 T1 SI2861229 T1 SI 2861229T1 SI 201331842 T SI201331842 T SI 201331842T SI 201331842 T SI201331842 T SI 201331842T SI 2861229 T1 SI2861229 T1 SI 2861229T1
Authority
SI
Slovenia
Prior art keywords
nicotinamide
tryptophan
pharmaceutical composition
composition containing
nicotinic acid
Prior art date
Application number
SI201331842T
Other languages
English (en)
Slovenian (sl)
Inventor
Georg Waetzig
Dirk Seegert
Original Assignee
Conaris Research Institute Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conaris Research Institute Ag filed Critical Conaris Research Institute Ag
Publication of SI2861229T1 publication Critical patent/SI2861229T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SI201331842T 2012-06-15 2013-06-14 Farmacevtski sestavek, ki vsebuje nikotinsko kislino in/ali nikotinamid in/ali triptofan, za pozitivno vplivanje na črevesno mikrobioto SI2861229T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102012011890 2012-06-15
EP13728758.7A EP2861229B1 (fr) 2012-06-15 2013-06-14 Composition pharmaceutique contenant de l'acide nicotinique et/ou nicotinamide et/ou tryptophane pour influencer positivement la microbiote intestinale
PCT/EP2013/062363 WO2013186355A1 (fr) 2012-06-15 2013-06-14 Composition pharmaceutique contenant un acide nicotinique et/ou de la nicotinamide et/ou du tryptophane pour influencer positivement le microbiote intestinal

Publications (1)

Publication Number Publication Date
SI2861229T1 true SI2861229T1 (sl) 2021-03-31

Family

ID=47002494

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201331842T SI2861229T1 (sl) 2012-06-15 2013-06-14 Farmacevtski sestavek, ki vsebuje nikotinsko kislino in/ali nikotinamid in/ali triptofan, za pozitivno vplivanje na črevesno mikrobioto

Country Status (32)

Country Link
US (2) US10426765B2 (fr)
EP (2) EP2861229B1 (fr)
JP (3) JP6855165B2 (fr)
KR (2) KR20150021071A (fr)
CN (2) CN108273064A (fr)
AR (1) AR091465A1 (fr)
AU (1) AU2013276451B2 (fr)
BR (1) BR112014030835B1 (fr)
CA (1) CA2876540C (fr)
CY (1) CY1123999T1 (fr)
DK (1) DK2861229T3 (fr)
ES (1) ES2859758T3 (fr)
HR (1) HRP20210090T1 (fr)
HU (1) HUE053359T2 (fr)
IL (1) IL236205B (fr)
IN (1) IN2014DN10260A (fr)
JO (1) JO3578B1 (fr)
LT (1) LT2861229T (fr)
MX (1) MX370795B (fr)
NZ (1) NZ702297A (fr)
PH (1) PH12014502744A1 (fr)
PL (1) PL2861229T3 (fr)
PT (1) PT2861229T (fr)
RS (1) RS61288B1 (fr)
RU (1) RU2657797C2 (fr)
SA (1) SA113340643B1 (fr)
SG (1) SG11201408251SA (fr)
SI (1) SI2861229T1 (fr)
SM (1) SMT202100248T1 (fr)
TW (1) TWI624260B (fr)
WO (1) WO2013186355A1 (fr)
ZA (1) ZA201408922B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2876540C (fr) 2012-06-15 2022-11-29 Conaris Research Institute Ag Composition pharmaceutique contenant un acide nicotinique et/ou de la nicotinamide et/ou du tryptophane pour influencer positivement le microbiote intestinal
SG11201510003VA (en) * 2013-06-05 2016-01-28 Univ British Columbia Anti-fibrogenic compounds, methods and uses thereof
ES2785399T3 (es) 2013-06-14 2020-10-06 Conaris Res Institute Ag Formulación de nicotinamida de liberación prolongada
WO2015086838A2 (fr) 2013-12-13 2015-06-18 Conaris Research Institute Ag Composition pharmaceutique contenant des combinaisons de nicotinamide et de 5-acide aminosalicylique pour influencer de manière bénéfique la microbiote intestinale et/ou traiter une inflammation gastrointestinale
EP2884282A1 (fr) 2013-12-13 2015-06-17 CONARIS research institute AG L'utilisation de tryptophane comme biomarqueur pour sélectionner des patients, dosage et suivi d'efficacité de traitement sur la flore intestinale et la manque de tryptophane
JP6895752B2 (ja) * 2013-12-13 2021-06-30 コナリス リサーチ インスティチュート アーゲー ニコチン酸および／またはニコチンアミドを含む、腸内微生物叢を改変することにより血中脂質レベルに有益に影響を及ぼすための医薬組成物
WO2015124637A1 (fr) * 2014-02-18 2015-08-27 Conaris Research Institute Ag Procédés et compositions pour transfert de micro-environnement intestinal
BR112016024400A2 (pt) * 2014-05-12 2017-08-15 Unilever Nv uso de niacinamida, niacinamida e método para melhorar a proteção do couro cabeludo
CN105287561A (zh) * 2015-11-25 2016-02-03 上海交通大学医学院附属瑞金医院 一种治疗溃疡性结肠炎的药物组合物
WO2017181102A1 (fr) * 2016-04-14 2017-10-19 ChromaDex Inc. Utilisation de nicotinamide riboside, d'acide nicotinique riboside, de nicotinamide mononucléotide et de dérivés de composé nicotinoyl dans du lait maternisé
EP3445340A1 (fr) 2016-04-19 2019-02-27 Ferring B.V. Compositions pharmaceutiques orales de mésalazine
BR112018071363A2 (pt) * 2016-04-19 2019-02-05 Ferring Bv composições farmacêuticas orais de nicotinamida
CN109718234A (zh) * 2017-10-31 2019-05-07 中国农业大学 L-色氨酸在缓解肠道炎症反应和屏障功能紊乱中的应用
CN108935981A (zh) * 2018-06-05 2018-12-07 西北农林科技大学 围产期奶山羊添加烟酰胺对羔羊糖脂代谢的影响及其机制
KR20220002260A (ko) * 2019-02-12 2022-01-06 메구미 타나카 유유아용 음식물, 유유아의 장내 환경의 개선 방법, 및 유유아의 면역력의 증강 방법
JP7493207B2 (ja) * 2019-03-28 2024-05-31 国立大学法人東北大学 がんの予防又は治療剤
CN113398130A (zh) * 2020-03-16 2021-09-17 广州市妇女儿童医疗中心（广州市妇幼保健院、广州市儿童医院、广州市妇婴医院、广州市妇幼保健计划生育服务中心） 烟酰胺用于预防和治疗胃肠道功能紊乱的用途
CN116635025A (zh) * 2020-11-27 2023-08-22 康纳里斯研究院股份公司 用于缩短covid-19和其他病毒感染患者的症状消退时间的烟酰胺、烟酰胺前体和烟酰胺代谢物及其组合物
EP4251157A1 (fr) * 2020-11-27 2023-10-04 CONARIS research institute AG Nicotinamide, précurseurs de nicotinamide et métabolites de nicotinamide et compositions de ceux-ci pour réduire le temps de résolution de symptômes chez des patients atteints de covid-19 et d'autres infections virales
WO2023002939A1 (fr) * 2021-07-19 2023-01-26 明治ホールディングス株式会社 Composition pour prévenir ou atténuer une maladie intestinale inflammatoire et composition pour réguler la flore bactérienne intestinale
CN118973562A (zh) * 2022-03-30 2024-11-15 康纳里斯研究院股份公司 用于预防或减轻感染性疾病的一种或多种急性后症状的包含烟酰胺、烟酰胺前体、烟酰胺代谢物或其组合的组合物
KR102789810B1 (ko) 2023-02-06 2025-03-31 한림대학교 산학협력단 아토피 피부염 진단용 바이오마커
CN117837697A (zh) * 2023-12-22 2024-04-09 汕头大学 一种烟酰胺的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
DE19524928A1 (de) * 1995-07-08 1997-01-09 Basf Ag Verfahren zur Rektifikation von Gemischen hochsiedender luft- und/oder temperaturempfindlicher Substanzen, die eine hohe Trennleistung erfordern, im Feinvakuum, sowie für dieses Verfahren geeignete Kolonnen
US5846983A (en) * 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5736532A (en) * 1996-02-14 1998-04-07 Furda; Ivan Multifunctional fat absorption and blood cholesterol reducing formulation comprising chitosan
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
HUP0104593A3 (en) * 1998-12-23 2004-10-28 G D Searle Llc Chicago Combinations of benzothiepine ileal bile acid transport inhibitor and nicotinic acid derivatives for cardiovascular indications
US6713057B1 (en) 1999-02-24 2004-03-30 The Johns Hopkins University Compositions and methods for modulating serum cholesterol
GB0015242D0 (en) 2000-06-22 2000-08-16 Nycomed Amersham Plc Stabiliser for radiopharmaceuticals
AU2001278699A1 (en) * 2000-08-08 2002-02-18 Shionogi And Co., Ltd. Inflammatory cytokine production inhibitors
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
US20060264409A1 (en) 2004-01-20 2006-11-23 Harty Richard F Compositions and methods of treatment for inflammatory diseases
CA2553775A1 (fr) 2004-01-20 2005-08-11 Richard F. Harty Compositions et procedes pour traiter des maladies inflammatoires
EP1751096A4 (fr) 2004-05-27 2009-01-07 Antibe Therapeutics Inc Sel d'acide 4- ou 5- aminosalicylique
DE602005010899D1 (de) * 2004-09-27 2008-12-18 Sigmoid Pharma Ltd Mikrokapseln mit einem methylxanthin und einem kortikosteroid
WO2007004613A1 (fr) 2005-07-01 2007-01-11 Ajinomoto Co., Inc. Agent thérapeutique contre l'affection abdominale inflammatoire et inhibiteur de la production de tnf-α
ES2418153T3 (es) * 2006-03-08 2013-08-12 Cortria Corporation Terapia de combinación con inhibidores no selectivos de COX para prevenir lesiones gástricas relacionadas con COX
ITMI20061932A1 (it) 2006-10-09 2008-04-10 Carlo Ghisalberti Complessi a trasferimento di carica per uso medicale
EP1935422A1 (fr) * 2006-12-20 2008-06-25 PEJO Iserlohn Heilmittel-und Diät-GmbH & Co.KG Composition pharmaceutique comprenant la nicotinamide ou l'acide nicotinique
WO2009051609A1 (fr) * 2007-10-19 2009-04-23 Pardee Joel D Traitement d'amélioration métabolique
EP2276491A4 (fr) * 2008-04-25 2011-08-17 Karolinska Inst Innovations Ab Nouvelle thérapie pour le traitement du syndrome du côlon irritable
RU2010151944A (ru) * 2008-05-20 2012-06-27 Серенис Терапьютикс С.А. (Fr) Ниацин и нспвс для комбинированной терапии
WO2009149058A2 (fr) 2008-06-02 2009-12-10 Dr. Reddy's Laboratories Ltd. Formulations de niacine à libération modifiée
CA2739465C (fr) 2008-10-03 2017-01-31 Dr. Falk Pharma Gmbh Compositions et procedes permettant de traiter les maladies intestinales a l'aide de mesalamine granulee
JP2011121889A (ja) 2009-12-09 2011-06-23 En Otsuka Pharmaceutical Co Ltd 炎症性腸疾患用アミノ酸組成物
JP2012102054A (ja) * 2010-11-11 2012-05-31 Kyodo Milk Industry Co Ltd 腸内ポリアミン増強剤
WO2012090224A1 (fr) 2010-12-29 2012-07-05 Nutracryst Therapeutics Private Limited Nouveaux co-cristaux/ sels moléculaires de mésalamine s'utilisant comme médicament anti-inflammatoire amélioré
CA2876540C (fr) 2012-06-15 2022-11-29 Conaris Research Institute Ag Composition pharmaceutique contenant un acide nicotinique et/ou de la nicotinamide et/ou du tryptophane pour influencer positivement le microbiote intestinal
ES2785399T3 (es) 2013-06-14 2020-10-06 Conaris Res Institute Ag Formulación de nicotinamida de liberación prolongada
BR112018071363A2 (pt) 2016-04-19 2019-02-05 Ferring Bv composições farmacêuticas orais de nicotinamida
EP4251157A1 (fr) * 2020-11-27 2023-10-04 CONARIS research institute AG Nicotinamide, précurseurs de nicotinamide et métabolites de nicotinamide et compositions de ceux-ci pour réduire le temps de résolution de symptômes chez des patients atteints de covid-19 et d'autres infections virales

Also Published As

Publication number Publication date
JP2022017332A (ja) 2022-01-25
HRP20210090T1 (hr) 2021-03-05
JP6855165B2 (ja) 2021-04-07
BR112014030835A2 (pt) 2017-06-27
US10426765B2 (en) 2019-10-01
KR20150021071A (ko) 2015-02-27
JP2019069972A (ja) 2019-05-09
MX370795B (es) 2020-01-08
RU2657797C2 (ru) 2018-06-15
CN108273064A (zh) 2018-07-13
CA2876540A1 (fr) 2013-12-19
DK2861229T3 (da) 2021-01-18
HUE053359T2 (hu) 2021-06-28
PL2861229T3 (pl) 2021-08-09
EP3831379B1 (fr) 2025-09-10
MX2014015217A (es) 2015-03-05
RS61288B1 (sr) 2021-02-26
EP3831379A1 (fr) 2021-06-09
KR102211832B1 (ko) 2021-02-02
PT2861229T (pt) 2021-01-05
EP2861229A1 (fr) 2015-04-22
SG11201408251SA (en) 2015-01-29
EP2861229B1 (fr) 2020-12-23
CN104363907A (zh) 2015-02-18
HK1204972A1 (en) 2015-12-11
IL236205B (en) 2020-02-27
LT2861229T (lt) 2021-01-25
BR112014030835B1 (pt) 2022-01-11
US20200009124A1 (en) 2020-01-09
NZ702297A (en) 2016-11-25
SA113340643B1 (ar) 2019-10-06
JO3578B1 (ar) 2020-07-05
TW201400116A (zh) 2014-01-01
TWI624260B (zh) 2018-05-21
IL236205A0 (en) 2015-01-29
PH12014502744A1 (en) 2015-02-02
CY1123999T1 (el) 2022-05-27
AU2013276451B2 (en) 2018-03-29
ZA201408922B (en) 2016-10-26
KR20200011619A (ko) 2020-02-03
CA2876540C (fr) 2022-11-29
RU2014148239A (ru) 2016-08-10
AR091465A1 (es) 2015-02-04
JP2015519388A (ja) 2015-07-09
WO2013186355A1 (fr) 2013-12-19
US20150126462A1 (en) 2015-05-07
ES2859758T3 (es) 2021-10-04
SMT202100248T1 (it) 2021-05-07
IN2014DN10260A (fr) 2015-08-07
AU2013276451A1 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
IL236205A0 (en) A pharmaceutical composition containing nicotinic acid and/or nicotamide and/or tryptophan to have a positive effect on the intestinal microbiota
IL236036A0 (en) Pyridinone and pyridizinone derivatives
IL230786A (en) Heterocyclic consequence and pharmacological drug
ZA201406233B (en) Pharmaceutical composition and administration thereof
PT3079675T (pt) Uma composição farmacêutica que contém ácido nicotínico e/ou nicotinamida para utilização para influenciar beneficamente os níveis de lípidos no sangue através da modificação da microbiota intestinal
PT2940014T (pt) Derivado 2,3-di-hidro-isoindol-1-ona como supressor da quinase btk e composição farmacêutica incluindo o mesmo
IL238060B (en) 2-aminopyridine derivatives, their preparation and pharmaceutical compositions containing them
IL233529A (en) 1, 5-Naphthyridine derivatives and lactose-containing pharmacological preparations
IL256646B (en) History of azaquinazoline carboxamides and pharmaceutical preparations containing them
IL235947A (en) Solid state isonicotinamide history and their medicinal preparations
ZA201305227B (en) Pharmaceutical composition comprising pyridone derivatives
IL245414A0 (en) A process for the preparation of methylphenidate and its pharmaceutical salts
PT2789607T (pt) Derivado de piridona e medicamento contendo o mesmo
SG11201406942SA (en) Trans-2-decenoic acid derivative and drug containing same
ZA201501095B (en) Pyridine derivative and medicine
PL399613A1 (pl) Pochodne estrów diarylowych kwasów 1-aminoalkanofosfonowych, sposób wytwarzania pochodnych estrów diarylowych kwasów 1-aminoalkanofosfonowych oraz ich zastosowanie
EP2930175A4 (fr) Nouveau dérivé d'octahydropyridoquinazoline, composition pharmaceutique le contenant, et utilisations pour ledit dérivé et ladite composition
IL234614B (en) Pharmaceutical composition and preparation method thereof
TH1401007439A (th) องค์ประกอบทางเภสัชกรรมที่มีนิโคตินิกแอซิด และ/หรือ นิโคตินาไมด์ และ/หรือ ทริปโตฟานเพื่อการมีอิทธิพลในด้านบวกต่อจุลชีพประจำถิ่นในลำไส้
ZA201408723B (en) Emulsion for pharmaceutical use and method for the production thereof